Dicerna Pharmaceuticals Announces First Quarter 2014 Financial And Operational Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced operational and financial results for the quarter ending March 31, 2014.

“2014 thus far has been highlighted by a series of important events for Dicerna. We recently announced the achievement of a major milestone in our company’s history with the initiation of a Phase 1 clinical trial of DCR-MYC in solid tumors and hematological malignancies.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC